Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner
Humacyte Inc HUMA
News
Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals
Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026
Humacyte Expands Board Expertise with Appointment of Scott Coward and Paul Kuznik
Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA
Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions
Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results
Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”
Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA
Humacyte To Announce 2026 Second Quarter Financial Results and Provide Business Update on August 12, 2026
Humacyte Announces FDA Acceptance of IND for First-In-Human Clinical Study of CTEV for Coronary Artery Bypass Grafting
Stocks to Watch: Oracle, Oxford Industries, Humacyte, PureCycle Technologies
Humacyte's Bioengineered Blood Vessel Hits Primary Endpoint in Phase 3 Trial
United States